A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 5/12/2010

Posted by | 4:39pm on Wednesday, May 12, 2010

:
Welcome to #socpharm chat. Plse start w/intros & why u are interested in pharma marketing & social media. 5/12/2010 19:04

:
@EileenOBrien I’ll try to join as an observer for my first #socpharm tweetup. It’s 2 am now in Spain and perhaps I say just silly things :-)

:
We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare them)

:
@itato Welcome! I don’t think anything is considered silly on Twitter :) #socpharm

:
#socpharm my 2nd week. im intrstd in pharma SM, specifically clinical trials

:
@ Irene, why are you interested in #socpharm? I work for an interactive agency focusing on rare disorder therapies.

:
@ Hi Dan, nice to see you again. #socpharm

:
T1: FDA encouraged docs to report “bad ads” done by pharma. Good idea? http://bit.ly/bkpDK4 #socpharm

:
T1: As @ said “Do physicians have time to report the diseases & adverse events they c, much less be on look out 4 bad ads? #socpharm

:
@ Fascinating! We work w/hemophilia, Acute Intermittent Prophyria & Primary Immune Disease & others #socpharm

:
Hi. Steve here, nice idea in theory don’t expect much follow thru #socpharm

:
#socpharm re docs reporting ads, i think its a terrible idea, just another way to have us telling on each other. communists did that too 5/12/2010 19:15

:
@ Have you ever checked out the #raredisease hashtag? Lots of interesting tweets there #socpharm 5/12/2010 19:16

:
T1: I was excited about the steps the “new” FDA was taking, but they lost me on this “bad ads” campaign. #socpharm 5/12/2010 19:16

:
#socpharm things like the FDA bad ads program will further discourage pharma from engaging with their consumers thru sm 5/12/2010 19:20

:
Clear SM regs would be helpful. #SocPharm 5/12/2010 19:21

:
@ Yes I did. Thanks for remember this hashtag.I’ve been in charge of Genzyme communicationsin Spian for the last year #socpharm 5/12/2010 19:22

:
T1: I dislike @ the “bad ads” campaign– docs should focus on MOA & their patients, not policing. this sours them in advance. #socpharm 5/12/2010 19:23

:
@ On the FDA docket is some SM guidelines by end of year. Fingers crossed “one click rule comes back” #socpharm 5/12/2010 19:23

:
@ Frieda Hernandez here from Siren Interactive. Don’t get the bad ads deal either #socpharm 5/12/2010 19:24

:
Yes, aware of pending guidelines. #SocPharm 5/12/2010 19:24

:
Sorry I’m late tonight…as for Q 1, I’ve had a mixed reaction to the “bad ads” campaign which I’ll explain #socpharm 5/12/2010 19:26

:
RT @: T1: I dislike @ the “bad ads” campaign– docs shd focus on MOA & their pts, not policing. this sours them in advance. #socpharm 5/12/2010 19:27

:
On one hand, I like the more open, social posture of the FDA and they should engage physicians in a more active capacity #socpharm 5/12/2010 19:28

:
@ Hi Joel, What do you hear from docs re FDA “bad ads” campaign? #socpharm 5/12/2010 19:29

:
Will the FDA offer compensation for the time? #socpharm 5/12/2010 19:31

:
@ same here on both fronts re: excitement and lost, bit of a headscratcher #socpharm 5/12/2010 19:31

:
Good point, time is $ for physicians RT @: Will the FDA offer compensation for the time? #socpharm 5/12/2010 19:32

:
T2: Ctr 4 Digital Democracy says drug cos shld not advertise in digi platforms incl 3rd party email http://bit.ly/9Smrmy Thoughts? #socpharm 5/12/2010 19:33

:
doctors don’t have time to police ads, that’s the FDA’s job, however the FDA could form a new physician advisory board for input #socpharm 5/12/2010 19:34

:
@ I’m interested in your perspective on “bad ads” #socpharm 5/12/2010 19:34

:
#socpharm i hope they dont offer $. the fda oughtta have their own ppl looking at this stuff. i mean how many ads could there pssbly be? 5/12/2010 19:34

:
@ You’d be surprised, between print & digital, HCP & consumer focused. But agree that’s FDA’s job. #socpharm 5/12/2010 19:35

:
T2 do they also want the elimination of all DTC? #socpharm 5/12/2010 19:36

:
CDD – a conservative approach. All sides should be listened to, considered, as regs developed. #SocPharm 5/12/2010 19:37

:
@ You’re right, but they don;t have enough so they’re looking for new recruits on the cheap #socpharm 5/12/2010 19:39

:
@ Agree. Hope patient orgs also provided input. NORD (@rarediseases) was supporter of online pharma role #socpharm 5/12/2010 19:40

:
Agree. #SocPharm 5/12/2010 19:41

:
@ #socpharm if i were a doctor, i’d be insulted, and perhaps go out of my way to NOT report what i thought might be a “bad ad” 5/12/2010 19:42

:
Anyone attend #BDI event? Biggest takeaway? Twitter transcript posted here, brill idea: http://bit.ly/aWK25y #socpharm 5/12/2010 19:44

:
@ Agreed #socpahrm #socpharm 5/12/2010 19:44

:
T2, like @ says, SM should be a 3 way convo, patient, HCP, pharma . Key is should be convo, not promo #socpharm # #hcsmeu 5/12/2010 19:46

:
RT @: T2, like @ says, SM should be a 3 way convo, patient, HCP, pharma . Key is should be convo, not promo #socpharm # #hcsmeu 5/12/2010 19:50

:
Twitter transcript is very useful.Thanks again @ #SocPharm I’ll send you our own transcript from the #hcsmeuES chats we do too 5/12/2010 19:52

:
@ I thought #BDI was a terrific event, much improved over last yr, the transcript shows the quality of #socpharm insights 5/12/2010 19:53

:
@ Gr8. Not a morning person so always miss & wasn’t sure whr 2 find #hcsmeu transcripts. Fan of @ @ #socpharm 5/12/2010 19:55

:
@ I couldn’t make it either year, but ths time the tweets seemed v excited. Much more chatter (well also more pple on twttr) #socpharm 5/12/2010 19:56

:
#socpharm If anyone speaks spanish,please join our twitter chats on healthcare social first steps in Spain. Every Tuesday 4pm CEST #hcsmeuES 5/12/2010 19:58

:
As always, I’ll post the transcript from #socpharm tonight on social pharmer community site: http://socialpharmer.ning.com 5/12/2010 19:58

:
RT @: T1: FDA encouraged docs to report “bad ads” done by pharma. Good idea? http://bit.ly/bkpDK4 #socpharm 5/12/2010 19:59

:
RT @: #socpharm If u speaks spanish, join our twitter chats on healthcare social 1st steps in Spain. Every Tuesday 4pm CEST #hcsmeuES 5/12/2010 19:59

:
@ takeaway @ #BDI was transparency / non-anon comms. @ put it well re: @ & @‘ models. #socpharm 5/12/2010 19:59

:
@ transparency and non-anon comm may help deal with T2 issues #socpharm 5/12/2010 20:01

:
RT @: #socpharm If anyone speaks spanish,please join our twitter chats on healthcare social first steps in Spain. Every Tuesday 4pm CEST #hcsmeuES 5/12/2010 20:02

:
Thanks 4 participating. Next Wed at 8 pm ET guest moderator will be Joyce Ercolino (@jearch) Dir of eBusiness at CSL Behring. #socpharm 5/12/2010 20:02

:
T1: “bad ads” = bad news most PCPs will not have the background needed to really document infractions. #socpharm 5/12/2010 20:02

:
@ agreed. that’s the big takeaway for me. HCPs want to know who is talking before they determine if they value a msg. #socpharm 5/12/2010 20:03

:
@ thanks & clearly I would agree – trust, transparency & non-anon communities like @ & @ were widely discussed #socpharm 5/12/2010 20:03

:
@ Good night. I’ll sign in the community asap. Today post related with FDA have been interesting to see next follow-up #socpharm 5/12/2010 20:04

:
@ @ Agreed! HCPs absolutely need to know whom they are communicating with & learning from #socpharm 5/12/2010 20:05

:
@ @ def! that’s why the KOL model works so well! I think that’s why @ & @ are so poised for growth #socpharm 5/12/2010 20:11

:
@ #ning has changed a lot ($ model). Maybe consider migrating to @ or @ to protect #socpharm content? cc: @ 5/12/2010 20:12

:
@ @ No brownie points allowed! #socpharm 5/12/2010 20:13

:
thanks all #socpharm 5/12/2010 20:15

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com